nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure
|
Persico, M. |
|
2016 |
48 |
S3 |
p. e233- 1 p. |
artikel |
2 |
Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis
|
Trauner, M. |
|
2016 |
48 |
S3 |
p. e236- 1 p. |
artikel |
3 |
Early changes in non-invasive assessment of liver fibrosis in hepatitis C virus-infected patients treated with DAAs: Preliminary reports
|
Iegri, C. |
|
2016 |
48 |
S3 |
p. e238-e239 nvt p. |
artikel |
4 |
Editorial Board
|
|
|
2016 |
48 |
S3 |
p. i- 1 p. |
artikel |
5 |
Emerging increase in the prevalence and severity of nonalcoholic fatty liver disease: Epidemiological study from general Mediterranean population
|
Petta, S. |
|
2016 |
48 |
S3 |
p. e238- 1 p. |
artikel |
6 |
Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis
|
Pasulo, L. |
|
2016 |
48 |
S3 |
p. e235- 1 p. |
artikel |
7 |
HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience
|
Shalaby, S. |
|
2016 |
48 |
S3 |
p. e237- 1 p. |
artikel |
8 |
Hepatitis C patients with any degree of portal hypertension are at risk to develop serious adverse effect to direct-acting antiviral therapies
|
De Luca, L. |
|
2016 |
48 |
S3 |
p. e234- 1 p. |
artikel |
9 |
Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study
|
Persico, M. |
|
2016 |
48 |
S3 |
p. e234- 1 p. |
artikel |
10 |
Liver biopsy in Type 2 Diabetes Mellitus: Steatohepatitis represents the sole feature of liver damage
|
Masarone, M. |
|
2016 |
48 |
S3 |
p. e237- 1 p. |
artikel |
11 |
New chitosan-coated liposomes for controlled release of active substances in HepG2 cells: Synthesis, biological characterization, cell viability and anti-inflammatory studies
|
Quagliariello, V. |
|
2016 |
48 |
S3 |
p. e236- 1 p. |
artikel |
12 |
Real life of DAAs (direct antiviral agents) for HCV infection in Friuli Venezia Giulia: Who, why, what, how did we treat?
|
Masutti, F. |
|
2016 |
48 |
S3 |
p. e238- 1 p. |
artikel |
13 |
TM6SF2 and MBOAT7 genotype to determine alcohol-related liver damage in patients with HCV chronic hepatitis
|
Degasperi, E. |
|
2016 |
48 |
S3 |
p. e235- 1 p. |
artikel |